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1. Introduction 
It has been estimated that diabetes will affect 439 million adults by 2030, with the major 
increase occurring in developing countries (Shaw et al., 2010). It is projected that it will rank 
as the 9th leading cause of death in low-income countries (Mathers & Loncar, 2006). There 
are two major types of diabetes, i.e. type 1 (T1D) or insulin dependent diabetes and type 2 
(T2D) or non-insulin dependent diabetes. The incidence of T2D is reaching epidemic 
proportions and has been associated with an increase in obesity (Venables & Jeukendrup, 
2009). According to the World Health Organisation (WHO, 2011) the main complications 
associated with diabetes are cardiovascular disease and renal failure. Although genetic 
factors may play a role, life-style factors, such as reduced exercise and poor diet, specifically 
a high carbohydrate, high fat diet devoid or low in fruit and vegetables, have been shown to 
increase the risk of diabetes (Astrup, 2001). 
Medicinal plants have been used in folk medicine and traditional healing systems such as 
Ayurveda and Traditional Chinese Medicine (TCM) for the treatment of diabetes (T.S.C. Li, 
2003; Modak et al., 2007; Singh et al., 2009; Yen et al., 2003). On the African continent as 
many as 90% of the populations of some countries relies on plants as the principal source of 
medicine for the treatment of different diseases, including diabetes (Hostettman et al., 2000), 
as they provide an affordable alternative to drugs. In South Africa a large number of plants, 
belonging to plant families such as the Asteraceae and Lamiaceae, amongst others, have 
been traditionally used for the treatment of diabetes (Deutschländer et al., 2009; Erasto et al., 
2005; Thring & Weitz, 2006).  
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Globally, there is a movement towards alternatives to single chemical entities as favoured 
by the pharmaceutical industry. These alternatives are rationally selected, carefully 
standardised, synergistic traditional herbal formulations and botanical drug products which 
are supported by robust scientific evidence (Patwardhan & Mashelkar, 2009). In many 
instances the value of herbal and medicinal plant extracts lies not in a single compound, but 
in their complex phytochemical nature. These complex mixtures of often unspecified 
compounds are able to modulate multiple targets (Y. Li et al., 2008). Antidiabetic phenolic 
compounds in the extracts also have the ability to ameliorate oxidative stress (Han et al., 
2007), an underlying mechanism to the pathogenesis of diabetes (Ceriello & Motz, 2004). 
One such compound is the xanthone C-glucoside, mangiferin (1,3,6,7-tetrahydroxy-xanthone-
C2-ǃ-D-glucoside), demonstrating antihyperlipidaemic, antihyperglycaemic and antioxidant 
properties (Wauthoz et al., 2007). Mangiferin (Fig. 1) was shown to protect against 
streptozotocin (STZ)-induced oxidative damage to cardiac and renal tissues in Wistar rats 
(Muruganandan et al., 2002). Its presence in the endemic South African Cyclopia spp. (family 
Fabaceae; tribe Podalyrieae) suggested the potential use of these plant species as antidiabetic 
nutraceuticals or even phytopharmaceuticals. Hesperidin (Fig. 1), another antioxidant and 
compound demonstrating hypoglycaemic properties in rodents (Akiyama et al., 2010; Jung et 
al., 2004), is also one of the major monomeric polyphenols present in Cyclopia spp. (Joubert et 
al., 2003). A decoction of Cyclopia spp. was used in the past as a restorative and as an 
expectorant in chronic catarrh and pulmonary tuberculosis. However, it is as the herbal tea, 
honeybush, that Cyclopia spp. are increasingly appreciated by consumers world-wide. The tea 
is primarily exported to the Netherlands, Germany, United Kingdom and United States of 
America. It is even exported to traditional tea-drinking countries such as Sri Lanka, India, 
Japan and China. Commercial herbal tea production comprised three main species, viz. C. 
genistoides, C. intermedia and C. subternata. Of these, C. intermedia, harvested almost exclusively 
from the wild, provides the bulk of honeybush production. 
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Fig. 1. Structures of phenolic compounds of C. intermedia extract. 
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A contributing factor to its growing popularity is the body of scientific evidence that 
honeybush has potential health benefits, including antioxidant, anticancer and 
phytoestrogenic properties (Joubert et al., 2008a). The greatest demand is for the traditional 
product, which is ‘fermented’ (oxidised) to form the characteristic dark-brown colour and 
sweet flavour. However, this is accompanied by a substantial reduction in the phenolic 
content of the plant material and extract, as well as a decrease in antioxidant activity 
(Joubert et al., 2008b), justifying investigating the benefits of unfermented C. intermedia for 
human health.  
With T2D being the most common form of diabetes, representing more than 90% of all cases 
(WHO, 2011), the antidiabetic potential of unfermented C. intermedia was investigated using 
a diet-induced obese insulin resistant (OBIR) rat model. Feeding rats a high fat diet induces 
a state of insulin resistance associated with impaired insulin-stimulated glycolysis and 
glycogen synthesis (Kim et al., 2000). The STZ-induced diabetic rat model, following 
pancreatic ǃ-cell destruction and resulting in insulin deficiency rather than insulin resistance 
(OBIR model), was used to establish the optimal acute glucose lowering dose of a C. 
intermedia extract. The investigation focused on a hot water extract of C. intermedia as it 
represents normal preparation of the herbal tea, albeit under more severe extraction 
conditions, but without introducing qualitative changes to composition as is the case for 
organic solvent extraction. 
2. Material and methods 
2.1 Chemicals 
General analytical grade laboratory reagents were purchased from Sigma-Aldrich (St. Louis, 
USA) and Merck (Darmstadt, Germany). Authentic reference standards were obtained from 
Sigma-Aldrich (mangiferin, hesperidin) and Extrasynthese (Genay, France; eriocitrin, 
luteolin). Isomangiferin was isolated from C. subternata (De Beer et al., 2009). Acetonitrile for 
HPLC analysis was gradient grade for liquid chromatography (Merck, Darmstadt, 
Germany). HPLC grade water was prepared by purifying laboratory grade water 
(Continental Water Systems Corp., San Antonio, USA) with a Milli-Q 185 Académic Plus 
water purification system (Millipore, Bedford, USA). 
STZ, fluothane, 50% dextrose solution, metformin hydrochloride and rosiglitazone maleate 
(Avandia®) were obtained from Sigma-Aldrich, AstraZeneca Pharmaceuticals 
(Johannesburg, South Africa), Intramed (Johannesburg, South Africa), Rolab (Johannesburg, 
South Africa) and GlaxoSmithKline (Bryanston, South Africa), respectively. 
2.2 Plant material and extract preparation 
Cyclopia intermedia shoots (ca 220 kg) were harvested according to normal practice by cutting 
the shoots sprouting from the rootstock directly above soil level. All the plant material was 
harvested from a natural stand on Nooitgedacht Farm in the Langkloof area, South Africa. The 
part of the stem without leaves or with only a few leaves (Fig. 2) was removed before further 
processing, entailing cutting of the shoots into small pieces (<4 mm) and mechanical drying at 
40 °C to less than 10% moisture content (Joubert et al., 2008b), giving ca 50 kg dried plant 
material. The plant material was pulverised with a Retsch rotary mill before pilot plant 
extraction. Water heated to >95 °C was added to the pulverised plant material in a 1:10 (m/v) 
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ratio and continuously stirred for 30 min. (final extract temperature was 70 °C), whereafter the 
extract was pumped to an in-line continuous centrifuge for removal of the insoluble matter. 
Following centrifugation, the extract, containing 2.69 g soluble matter/100 mL, was cooled to 
ca 20 °C using a tubular heat exchanger and aliquots bottled for daily feeding of OBIR rats. 
The aliquots were stored at -20 °C until use. An aliquot (ca 1000 mL) was freeze-dried in an 
Edwards Modulyo bench-top freeze-drier (Edwards High Vacuum Ltd, Crowley, UK) for 
acute dosing of STZ-induced diabetic rats and for phenolic content analysis. 
 
 
                                           (a)                                                                   (b) 
Fig. 2. (a) Cyclopia intermedia plant showing aerial parts (top section of a typical shoot with thin 
stems and leaves). (b) Harvested shoots before removal of the stem parts without leaves. 
2.3 HPLC analysis of extract 
HPLC analysis was performed using an Agilent 1200 series HPLC system consisting of a 
quaternary pump, autosampler, in-line degasser, column oven and diode-array detector 
(Agilent Technologies Inc., Santa Clara, USA) controlled with Chemstation 3D LC software. 
Separation was performed on a Zorbax Eclipse XDB-C18 column (150 x 4.6 mm, 5 m 
particle size, 80 Å pore size) from Agilent Technologies protected by a guard column with 
the same stationary phase. The separation was achieved with mobile phases consisting of 
0.1% formic acid and acetonitrile using the solvent gradient reported previously (De Beer & 
Joubert, 2010). The flow-rate and column temperature were maintained at 1 mL/min and 30 
°C, respectively. The freeze-dried extract was dissolved in 16% DMSO (ca 5 mg/mL) and 
filtered using a 33 mm Millex-HV PVDF syringe filter unit with 0.45 m pore size 
(Millipore) before injection (20 L). Compound identification was based on retention times 
and UV-Vis spectra of authentic standards where available (mangiferin, isomangiferin, 
eriocitrin, hesperidin, luteolin and hesperetin). An additional peak was identified as an 
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eriodictyol-glucoside based on similarity of its retention time and UV-Vis spectrum with a 
compound identified previously using liquid chromatography with mass spectrometric 
detection (De Beer & Joubert, 2010). An unidentified compound was also observed, which 
had retention time and UV-Vis characteristics similar to a compound previously detected in 
several Cyclopia spp. (De Beer & Joubert, 2010). Mangiferin, isomangiferin and luteolin were 
quantified using the peak areas at 320 nm, while the eriodictyol-glucoside, eriocitrin, 
hesperidin, hesperetin and the unidentified compound were quantified using the peak areas 
at 288 nm. A calibration series consisting of mangiferin (0.05-2.5 µg injected), isomangiferin 
(0.05-2.5 µg injected), eriocitrin (0.01-0.8 µg injected), hesperidin (0.01–1.5 µg injected), 
hesperetin (0.003-0.25 μg injected) and luteolin (0.05-0.35 µg injected) was used for external 
calibration. The eriodictyol-glucoside was quantified in terms of eriocitrin equivalents, 
while the unidentified compound was quantified in terms of hesperidin equivalents. 
2.4 Animal study  
Ethical approval was obtained from the Ethics Committee for Research on Animals (ECRA) 
of the Medical Research Council of South Africa. 
Male Wistar rats, obtained from the Primate Unit of the Medical Research Council 
(Tygerberg, South Africa), were used throughout the study. The rats were housed 
individually in wired top and bottom cages, fitted with PerspexTM houses and kept in a 
controlled environment of 23–24 °C, 50% humidity and a 12 h light/dark cycle. 
2.4.1 STZ-induced diabetic rats  
Adult male Wistar rats (200-250 g) were injected intramuscularly with freshly prepared STZ 
[35 mg/kg body weight (BW)] in 0.1 M citrate buffer (pH 4.5) to induce stable non-
ketoacidotic diabetic rats. Blood samples were taken from the tail tip 72 hrs after STZ 
injection and the plasma glucose concentrations determined using a glucometer (Precision 
Q.I.D, Abbott Laboratories, Johannesburg, South Africa). Rats with fasting blood glucose 
levels of >15.0 mmol/L were considered diabetic and were selected for the acute dose 
finding study of the extract. 
2.4.2 Acute dosing of diabetic STZ rats with honeybush extract 
The efficacy of a single dose of honeybush extract was determined by administering 
different doses of freeze-dried extract to STZ diabetic rats. Following a 3 hr fast, baseline 
plasma glucose concentrations of diabetic STZ rats were determined. The freeze-dried 
honeybush extract (reconstituted in a fixed volume of distilled water yielding e.g. 5 mg/mL 
for the 5 mg/kg BW dose, etc.) was administered by oral gavage under light anaesthesia (by 
inhalation of 2% fluothane with 98% oxygen) to four experimental groups of five STZ rats 
each at doses of 0 (vehicle control), 5, 25 and 50 mg/kg BW. Plasma glucose concentrations 
were determined hourly over a 6 hr period. 
2.5 Chronic treatment of OBIR rats with honeybush extract  
The efficacy of honeybush extract to ameliorate diet-induced insulin resistance, characterised by 
hyperglycaemia, hyperinsulinaemia, hyperglucagonaemia and dyslipidaemia was investigated 
using OBIR Wistar rats chronically exposed to the extract for 12 wks (described below). 
www.intechopen.com
 
Phytochemicals – Bioactivities and Impact on Health 
 
318 
2.5.1 Inducing insulin resistance in Wistar rats 
Three-week old weanling Wistar rats (male) were fed a 40% high fat diet (Table 1) and 30% 
sucrose in their drinking water ad libitum for 9 wks. The high fat diet in combination with 
sucrose induces insulin resistance and obesity with slightly elevated fasting glucose 
concentrations (Hallfrisch et al., 1981; Krygsman et al., 2010). After 9 wks on the high fat and 
sucrose diet, blood was collected for baseline glucose and insulin determination. Thereafter 
the rats were allocated into experimental groups and maintained on the high fat and sucrose 
diet during the subsequent 12-wk treatment. 
2.5.2 Experimental groups  
The untreated control consisted of six 12-wk old OBIR rats that were randomly assigned to 
the control group.  
Groups E1 – E5 (honeybush extract treated groups) consisted of five groups of ten OBIR rats 
each, receiving 538, 1075, 1792, 2150 or 2688 mg/100 mL honeybush extract (hot water 
soluble solids), respectively, as their drinking fluid, which also contained 30% sucrose 
(Table 2). The daily fluid intake was measured for each rat and the average amount of liquid 
 
Nutrients % Energy 
Protein 15.09 
Fat 40.17 
Saturated fatty acids 18.27 
Monounsaturated fatty acids 11.45 
Polyunsaturated fatty acids 5.75 
Carbohydrate 44.73 
Kcal/g of food 2.06 
Kcal/g of sucrose 0.60 
Total energy of diet (Kcal/g) 2.66 
Table 1. High fat diet (HFD) macronutrient and calorific composition. 
 
Group Weight Treatment 
concentration
Fluid 
intake 
Treatment 
intake/day
Mangiferin 
intake/day
Hesperidin 
intake/day 
Control 476 ± 20 – 30 ± 2 – – – 
E1 441 ± 12 538 33 ± 4   77.2 ±   9.6   4.47 ± 0.55 0.27 ± 0.03 
E2 456 ± 20 1075 42 ± 5 206.9 ± 27.5 11.99 ± 1.60 0.73 ± 0.10 
E3 442 ± 25 1792 31 ± 4 255.1 ± 64.6 14.79 ± 3.74 0.65 ± 0.23 
E4 438 ± 21 2150 32 ± 2 299.1 ± 23.5 17.33 ± 1.36 1.06 ± 0.08 
E5 457 ± 36 2688 43 ± 2 531.3 ± 61.1 30.79 ± 3.54 1.88 ± 0.22 
Met 489 ± 22 – 31 ± 4 22.0 – – 
Rosi 479 ± 26 – 29 ± 2   4.0 – – 
Table 2. OBIR rat body weight (g), extract concentration (mg/100 mL), fluid intake (mL), 
treatment intake (mg/kg BW), i.e. C. intermedia extract (E1-5), metformin (Met) or 
rosiglitazone (Rosi), as well as equivalent intake of mangiferin (mg/kg BW) and hesperidin 
(mg/kg BW), for chronic treatment experiment. 
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consumed per week for each rat was calculated (Table 2). Aliquots of the aqueous 
honeybush extract were defrosted daily. In the case of E1 to E4 the extract was diluted with 
water to give the required concentration of hot water soluble solids, while E5 represented 
the undiluted extract. 
The metformin and rosiglitazone treated groups consisted of three OBIR rats each that 
received metformin hydrochloride or rosiglitazone maleate at dosages of 22 and 4 mg/kg 
BW, respectively, in distilled water. 
2.5.3 Blood parameters 
Determination of fasting plasma glucose. The STZ-induced diabetic and OBIR rats were fasted 
for 3 hrs and overnight, respectively, prior to determining their fasting plasma glucose 
concentrations. A drop of blood was collected from the tail tip and the plasma glucose 
concentration determined. 
Determination of fasting serum insulin. Rats were anaesthetised by 2% fluothane inhalation 
with 98% oxygen. Blood was collected from the tail tip into Eppendorf tubes and stored on 
ice until centrifuged at 2500 rpm for 15 min. at 4 °C. Following centrifugation, the serum 
samples were stored at -20 °C until analysis. The serum insulin concentration was 
determined by radioimmunoassay using a rat insulin measurement kit from Linco® 
Research (St. Charles, USA). 
Intravenous glucose tolerance test (IVGTT). Rats fasted overnight were anaesthetised as 
described above and a drop of blood obtained from the tail tips. This was used for 
measuring baseline glucose. Glucose (50% dextrose solution), at a dose of 0.5 mg/kg BW, 
was injected intravenously over 20 sec and glucose measurements taken at 5, 10, 20, 30, 40, 
50 and 60 min. 
Determination of fasting plasma cholesterol. Rats were anaesthetised as described above and 
blood, collected from the tail tips, was prepared and stored at -20 °C for analysis. Total 
cholesterol concentrations were determined by Pathcare Laboratories (Cape Town, South 
Africa), using a Bayer-Technicon RA 1000 auto-analyser. 
2.5.4 Immunocytochemistry and image analysis of the pancreata  
Harvesting of pancreata. After 12 wks of treatment the rats were euthanised by exsanguination 
under sodium barbital anaesthesia and pancreata harvested. The whole pancreas was 
removed, fixed overnight in 4% buffered formaldehyde (pH 7.5) and processed into paraffin 
wax by standard histological methods. Serial 4 μm thick sections were cut for 
immunocytochemistry. 
Immunocytochemistry. Serial wax sections attached onto silane coated slides were de-waxed 
with xylene and hydrated through descending grades of ethanol into water. Slides were rinsed 
in 50 mM Tris–buffered-saline (pH 7.4) and double immuno-stained, using anti-insulin and 
anti-glucagon primary antibodies. Primary antibody binding to insulin or glucagon was 
detected by avidin D-biotinylated horseradish peroxidase or streptavidin-biotin-
complex/alkaline phosphatase conjugated link antibodies. Insulin positive labeling (ǃ-cells) 
was visualised with fuchsin red and ǂ-cells with diaminobenzidine tetrahydrochloride. 
Method controls involved omission of the primary antibody (anti-insulin or anti-glucagon). 
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Image analysis. Both ǃ- and ǂ-cell areas were measured on each section (minimum of ten 
sections per group). Computer-assisted measurements were taken with a Canon Powershot 
S40 digital camera (Tochigi, Japan) mounted on an Olympus BX60 light microscope (Tokyo, 
Japan), attached to a personal computer to capture images. The acquired images were 
transferred to the computer using remote capture software from Canon. Image analysis was 
performed with Leica Qwin Plus Software (Cambridge, UK). The ratio of either the ǃ-cell 
positive or the ǂ-cell positive area to the total pancreas area was calculated. ǃ-Cell and ǂ-cell 
sizes were calculated by dividing the total area of each of the cell types by the number of 
nuclei counted. 
2.6. Statistical analysis  
Results were entered into an Excel spreadsheet and statistically analysed. For the acute STZ 
rat experiment hourly (t = 1–6) glucose concentrations were compared against baseline (t = 
0) and the control for each corresponding time point. For the chronic OBIR rat experiments 
each data point was compared to the corresponding control value using ANOVA with a 
Dunnet post-hoc test (Prism version 5, Graphpad software®). The values presented are the 
mean ± SE. 
3. Results 
3.1 Extract composition  
The phenolic compound structures for the major compounds of the C. intermedia extract are 
shown in Fig. 1, the plant shoots in Fig. 2 and the extract HPLC profile and quantitative data 
in Fig. 3. The major compounds detected included the xanthone isomers, mangiferin and 
isomangiferin, the flavanone glycoside, hesperidin (hesperetin-7-O-rutinoside), and an 
unidentified compound previously detected in several Cyclopia spp. (De Beer & Joubert,  
2010). Additionally, a flavone, luteolin, and three flavanones, namely an eriodictyol- 
 
 
Fig. 3. Phenolic profile and phenolic composition (g/100 g) of C. intermedia extract (1, 
unidentified compound; 2, mangiferin; 3, isomangiferin; 4, eriodictyol-glucoside; 5, 
eriocitrin; 6, hesperidin; 7, luteolin; 8, hesperetin). 
0
50
100
150
200
250
300
0 5 10 15 20 25 30
A
b
so
rb
a
n
ce
 a
t 
2
8
8
 n
m
 (
m
A
U
)
Time (min)
1
6
5
43
2
7
8
Compound Content 
(g/100 g) 
1 1.105 
2 5.796 
3 1.567 
4 0.176 
5 0.037 
6 0.354 
7 0.023 
8 0.068 
www.intechopen.com
Assessment of the Antidiabetic Potential of an Aqueous Extract 
of Honeybush (Cyclopia intermedia) in Streptozotocin and Obese Insulin Resistant Wistar Rats 
 
321 
glucoside, eriocitrin (eriodictyol-7-O-rutinoside) and hesperetin, the aglycone of hesperidin, 
were also detected in small quantities.  
3.2 Animal study 
Results of the intake data are summarised in Table 2. The average intake of honeybush 
extract by the various treatment groups varied from 77 to 531 mg/kg BW. This equals 4.5 to 
30.8 mg/kg BW of the major xanthone, mangiferin, and 0.3 to 1.9 mg/kg BW of the major 
flavanone, hesperidin. 
Intramuscular injection of Wistar rats with STZ (35 mg/kg BW) induced diabetes in the rats 
at an average fasting plasma glucose concentration of 27.8 ± 1.0 mmol/L (data not shown). 
The acute effects of administering the honeybush extract by oral gavage under light 
anaesthesia at doses of 0 (vehicle control), 5, 25 and 50 mg/kg BW are shown in Fig 4. The 
optimal acute oral glucose lowering dose for the honeybush extract in STZ-induced diabetic 
rats for the dose range tested was 50 mg/kg BW. This was the only acute dose of the extract 
that significantly reduced the mean blood glucose concentrations relative to the baseline 
fasting blood glucose concentration. Reductions of 33.5 ± 1.7% (p<0.05), 34.3 ± 3.6% (p<0.05) 
and 35.6 ± 3.5% (p<0.01) were observed after 4, 5, and 6 hrs, respectively (Fig. 4). 
After a chronic 3-month treatment of OBIR rats with aqueous honeybush extract their 
hyperglycaemic fasting blood glucose concentrations were reduced to normoglycaemic 
values. In other words, the honeybush extract reduced the fasting blood glucose levels from 
12.2 mmol/L of the control to 4.8 – 5.4 mmol/L (p<0.001). All extract concentrations were 
effective. Metformin and rosiglitazone had very similar effects and reduced the fasting 
glucose to 6.3 mmol/L (p<0.001) and 5.6 mmol/L (p<0.001), respectively (Fig. 5). 
Untreated control OBIR rats had IVGTT peak glucose concentrations of 18.2 ± 1.74 mmol/L. 
Treatment with the honeybush extract reduced this value to 14.9 ± 0.7 mmol/L (treatment 
E2, p<0.05), 14.8 ± 0.9 mmol/L (treatment E3, p<0.05) and 13.5 ± 1.2 mmol/L (treatment E4, 
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Fig. 4. Acute glucose lowering effect of C. intermedia extract in STZ diabetic rats (n=5). 
Significant differences from baseline indicated with * (p<0.05) or ** (p<0.01). 
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Fig. 5. The effect of chronic treatment with C. intermedia extract, metformin and rosiglitazone 
(see Table 2 for treatment codes and dosage) on fasting plasma glucose concentration of 
OBIR rats (n=10). Significant differences from control indicated with *** (p<0.001). 
p<0.05), respectively (only E3 is shown for clarity; Fig. 6). The IVGTT area under the curve 
values were reduced from 670 ± 9 for the control to 474 ± 15 (p<0.05) and 496 ± 13 (p<0.05) 
for E2 and E5, respectively (data not shown). E1 (the lowest dose), as well as the known 
drugs, metformin and rosiglitazone, had no significant effect (p≥0.05) (Fig. 6). 
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Fig. 6. The effect of C. intermedia extract, metformin (Met) and rosiglitazone (Rosi) treatment 
on intravenous glucose tolerance in OBIR rats (n=10) (see Table 2 for treatment codes and 
dosage). E3 differs significantly from the control as indicated with * (p<0.05). 
Treatment of OBIR rats with honeybush extracts, E1 to E5, for 3 months lowered the total 
plasma cholesterol concentration compared to the untreated rats (2.9 ± 0.3 mmol/L) by 31.6 - 
39.1% (Fig. 7). The effect of metformin and rosiglitazone on total cholesterol was not 
determined. 
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Fig. 7. The effect of chronic treatment with C. intermedia extract (see Table 2 for treatment 
codes and dosage) on fasting total cholesterol concentrations in OBIR rats (n=10). Significant 
differences from control indicated with * (p<0.05) or ** (p<0.01). 
The average ǂ-cell size in untreated OBIR rats was 106 ± 13.6 μm2. Treatment with the 
honeybush extracts, E1 to E4, reduced the ǂ-cell size to about half, i.e. to 48.4 – 54.9 μm2 
(p<0.01). Metformin and rosiglitazone had similar effects and also reduced the average ǂ- 
cell size to 41.2 ± 1.9 μm2 and 44.0 41.2 ± 1.9 μm2, respectively (p<0.01) (Fig. 8). No data were 
available for E5. These changes in the ǂ-cell size were also reflected in the decreased ǂ-cell to 
ǃ-cell ratio for all treatments (Fig. 9).  
 
 
0
20
40
60
80
100
120
140
Control E1 E2 E3 E4 Met Rosi
M
e
a
n
 c
e
ll
 s
iz
e
 (
m
2
)
**
****
****
**
 
 
Fig. 8. The effect of chronic treatment with C. intermedia extract, metformin and rosiglitazone 
(see Table 2 for treatment codes and dosage) on mean ǂ-cell size in the pancreata of OBIR 
rats (n=10). Significant differences from control indicated with ** (p<0.01). 
www.intechopen.com
 
Phytochemicals – Bioactivities and Impact on Health 
 
324 
 
0
0.1
0.2
0.3
0.4
0.5
Control E1 E2 E3 E4 Met Rosi
R
a
ti
o
**
**
***
** * **
 
Fig. 9. The effect of chronic treatment with C. intermedia extract, metformin and rosiglitazone 
(see Table 2 for treatment codes and dosage) on ǂ- to -cell ratio in the pancreata of OBIR 
rats (n=10). Significant differences from control indicated with * (p<0.05), ** (p<0.01) or *** 
(p<0.001). 
4. Discussion 
The content of mangiferin, isomangiferin and the unidentified compound was higher than 
the average for unfermented C. intermedia extracts previously analysed (De Beer & Joubert, 
2010; Joubert et al., 2008b), while the hesperidin and eriocitrin contents of the present extract 
were lower. De Beer & Joubert (2010) detected luteolin only in trace amounts, while no 
hesperetin was detected. Joubert et al. (2003) found that the plant material (dry mass basis) 
contain 1.69% mangiferin, while isomangiferin and hesperidin, respectively, comprised 0.22 
and 1.76% of the dry plant material. Other phenolic compounds of C. intermedia include 
flavones, isoflavones, other flavanones and coumestans (Ferreira et al., 1998; Kamara et al., 
2003). Quantitative differences between the present extract and aqueous hot water extracts 
analysed previously (De Beer & Joubert, 2010; Joubert et al., 2008b) could be attributed to 
natural variation and/or selective use of the upper part of the shoot. This has implications 
for standardisation and efficacy. Testing of more C. intermedia extracts, specifically for their 
efficacy as antidiabetic extracts, is required before more comprehensive claims can be made. 
STZ was originally developed as an antibiotic derived from Streptomyces achromogenes but it 
is toxic to pancreatic ǃ-cells. It selectively enters insulin producing ǃ-cells via their GLUT2 
glucose transporter proteins, inducing irreparable DNA damage and death of ǃ-cells in a 
dose dependent manner (Lenzen, 2008). In the Wistar rat, intramuscular injection of STZ (35 
mg/kg BW) increased fasting plasma glucose concentrations by ca 500% from the average 
normoglyceamic concentration of 5.3 mmol/L, resulting in stable non-ketoacidotic T1D 
diabetic rats. An acute 50 mg/kg BW dose of the aqueous honeybush extract induced a 
sustained glucose lowering effect from 3 to at least 6 hrs in these STZ-induced diabetic rats. 
These results are comparable to that of Miura et al. (2001) who assessed the acute 
antidiabetogenic effect of an extract of Anemarrhena aspholoides in a hyperglycaemic KK-Ay 
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diabetic mouse model. This plant, which contains the xanthones, mangiferin and a 7-
glucoside of mangiferin, is used as an Oriential medicine for the treatment of diabetes. After 
oral treatment the maximal glucose lowering effect of the aqueous Anemarrhena aspholoides 
extract was achieved after 7 hrs. Mangiferin and its glucoside showed similar activity at a 
dose of 90 mg/kg BW. Mangiferin administered intraperitoneally for 30 days to mildly 
hyperglycaemic STZ-induced rats at doses of 10 and 20 mg/kg BW ameliorated the diabetic  
effects including weight loss, hyperglycaemia and hypercholesterolaemia (Dineshkumar et 
al., 2010). Prior to the latter study, the antidiabetic effects of mangiferin in STZ-induced 
diabetic Wistar rats were shown at the same doses after chronic treatment for 14 and 28 days 
(Muruganandan et al., 2005). 
In the present study 50 mg/kg BW of honeybush extract, equalling a dose of 2.90 mg 
mangiferin, was effective at reducing plasma glucose concentrations in our STZ-induced 
diabetic rat model. Other compounds in the extract could also contribute to the observed 
hypoglycaemic effect through synergistic or additive effects. Hesperidin, in particular, 
comprising 0.35% of the honeybush extract, was shown to have a hypoglycaemic effect in 
marginally hyperglycaemic Wistar rats normalising their blood glucose concentrations after 
16 days (Akiyama et al., 2010). Jung et al. (2004), using a spontaneously diabetic C57BL/KsJ-
db/db mouse model, showed that a 5-wk supplementation of the diet with 0.02% 
hesperidin ameliorated the development of hyperglycaemia in these mice. Both Akiyama et 
al. (2010) and Jung et al. (2004) attributed the hypoglycaemic effect of hesperidin to 
upregulation of glucose regulating enzymes, in particular glucokinase, which enhances 
glycolysis and increases glycogen synthesis. 
Confirmation of the antidiabetic potential of C. intermedia extract in the STZ-induced 
diabetic rat model was followed up with a chronic study in the high fat diet-induced OBIR 
rat model. Feeding non-predisposed Wistar rats a high fat (Table 1) and sucrose diet from 
weanling for three months induces obesity and glucose intolerance. Although these obese 
rats maintain near normal fasting glucose levels they present with hyperinsulinaemia,  
hyperglucagonaemia and dyslipidaemia (Buettner et al., 2006; Chalkley et al., 2002; 
Kamgang et al., 2005). The addition of refined sugars, i.e. sucrose, exacerbates the metabolic 
aberrations by the disruption of fatty acid metabolism resulting in hepatic and subsequent 
muscle insulin resistance (Fukuchi et al., 2004). The chronic hyperinsulinaemia associated 
with insulin resistance increases hepatic lipogenesis due to increased expression of the 
major lipogenesis gene sterol response element-binding protein 1c (SREBP1c). In these obese 
rats increasing levels of glucagon fail to regulate the insulin action, leading to increases in 
hepatic fat accumulation and hypertriglyceridaemia (Buettner et al., 2006). Interestingly, 
whereas the insulin sensitivity of the SREBP1c pathway is retained, the forkhead box protein 
O1 (FOXO1) pathway becomes insulin resistant, resulting in decreased hepatic glucose 
uptake and increased gluconeogenesis. Together the increase in fatty acid synthesis and 
hepatic glucose release worsens muscle and pancreatic islet insulin resistance (Liu et al., 
2011). Ultimately, high fat feeding is directly associated with pancreatic endocrine 
dysfunction and subsequent morphological changes of the pancreatic islets’ endocrine cell 
ratios and cell sizes. The compensatory response to the increased demand for insulin results 
in pancreatic ǃ-cell hypertrophy and an increase in ǂ-cell number and volume (Buettner et 
al. (2007). As the diabetic pathogenesis worsens the ǃ-cell mass declines and the ǂ- to ǃ-cell 
ratio increases (Liu et al., 2011). Feeding the same 40% high fat diet to pregnant Wistar dams 
during gestation resulted in offspring with similar increases in ǂ-cell volume, while ǃ-cell 
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volume decreased (Cerf et al., 2005). In human T2D pancreatic islets, larger islets with an 
increased proportion of pancreatic ǂ-cells have been shown to have impaired function  
(Deng et al., 2004). Despite the diet-induced metabolic and morphological aberrations these 
rats only develop slight hyperglycaemia over time without progressing to overt T2D. The 
similarities of the diet-induced OBIR rat to the pathophysiology of human obesity and the 
metabolic syndrome are well established (Buettner et al., 2007) and this animal model was 
therefore selected to test the possible ameliorating effects of honeybush extract on these 
metabolic aberrations. 
Inclusion of the honeybush extract in an otherwise diabetogenic diet for OBIR rats resulted 
in normalisation of the pre-existing hyperglycaemia over a wide range of dosages. This 
confirms that the extract has glucose lowering potential without causing hypoglycaemia. 
The latter is a potentially undesirable side effect of some T2D agents, specifically the 
sulfonylureas and meglitinides (Bennett et al., 2011). In addition, the normoglycaemic effect 
of the honeybush extract was achieved without dietary intervention. The extract proved to 
be as effective as metformin and rosiglitazone, which are regarded as the gold standards for 
treating human T2D. The efficacy of the extract at all doses and the lack of a clear dose 
response could be contributed to the length of the treatment (12 wks) and relative high 
doses even at the lowest dosage level. The reduction in IVGTT peak values and the area 
under the curve values in OBIR rats treated with the honeybush extract clearly indicated 
improved glucose homeostasis. Further, the improvement in glucose control was not 
associated with significantly increased fasting insulin concentrations. This may suggest that 
the mechanism whereby the extract elicits its effect on glucose metabolism is independent of 
insulin, reflecting adaptive mechanisms in the fasted state. This would imply that, due to the 
low fasting glucose concentrations, ǃ-cells need to release less insulin to maintain glucose 
homeostasis.  
Plasma cholesterol levels of honeybush extract treated OBIR rats were significantly reduced 
when compared with the plasma cholesterol levels of the untreated control rats. Mangiferin 
and hesperidin have been shown to lower plasma cholesterol levels of diabetic rats 
(Akiyama et al., 2010; Dineshkumar et al., 2010; Muruganandan et al., 2005). Mangiferin, 
apart from lowering total cholesterol, also increases high-density lipoprotein-cholesterol 
levels and therefore decreases the atherogenic index in diabetic rats (Muruganandan et al., 
2005). The hypolipidaemic effect of hesperidin has been attributed to the inhibition of 
hepatic 3-hydroxy-3-methyl-glutaryl-CoA reductase and acyl CoA:cholesterolacyl 
transferase, key enzymes in cholesterol synthesis and cholesterol esterification, resulting in 
the reduction of plasma cholesterol (Bok et al., 1999; Jung et al., 2006). Finally, a potential 
role of some minor compounds such as the inositol, (+)-pinitol, shown to be present in C. 
intermedia plant material (Ferreira et al., 1998), in the glucose- and cholesterol-lowering 
effects (Bates et al., 2000; Choi et al., 2009) elicited by the honeybush extract cannot be 
excluded. 
World-wide over 18 million people have died of cardiovascular disease in 2005. WHO has 
identified high total cholesterol as a major contributing risk factor which is modifiable and 
thereby could potentially reduce the incidence of cardiovascular disease (Rodgers et al., 
2004; Roth et al., 2011). Polyphenols have anti-atherosclerotic properties and are protective 
against cardiovascular disease. Apart from their plasma cholesterol lowering effects, 
polyphenols are associated with improved endothelial function and oxidative status 
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(Badimon et al., 2010). The protective effects of dietary flavonol intake against coronary 
heart disease mortality in humans was highlighted in a meta-analysis (Huxley & Neil, 2003), 
indicating a 20% lower risk in individuals with the highest consumption of dietary 
flavonols. In another study, Peters et al. (2001) suggested drinking three cups of tea (Camellia 
sinensis) a day could reduce the risk of myocardial infarction by 11%. In human trials 
coronary artery disease patients have shown improved endothelial function and coronary 
microcirculation following polyphenolic treatment (Hozumi et al., 2006). 
The main morphometrical finding following honeybush treatment for 12 wks was a 
decrease in the ǂ-cell area, and subsequently by inference, total pancreas ǂ-cell volume. The 
role of glucagon in the pathogenesis of T2D has been largely neglected by researchers. In 
mice, persistent hyperglucagonaemia induced by glucagon-producing glucagonomas results 
in T2D (Y. Li et al., 2008). Glucagon secretion by the ǂ-cell is tightly regulated by insulin via 
insulin receptors at the surface of ǂ-cells. This ensures that normoglycaemia is maintained. 
However, as insulin resistance increases, as is the case with the OBIR rat model, 
dysregulation of glucagon secretion by insulin occurs, resulting in persistent 
hyperglucagonaemia. Morphologically, this results in increased ǂ-cell numbers, ǂ-cell 
volume and glucagon secretion that worsen the insulin resistance of the liver causing more 
hyperglycaemia and T2D (Liu et al., 2011). Honeybush extract treatment reduced the 
average ǂ-cell size and subsequently the total ǂ-cell area leading to an improved ǂ- to ǃ-cell 
ratio in OBIR rats. The reduction of ǂ-cell size and therefore glucagon secretion can have 
profound effects on glucagon induced insulin secretion and thereby alleviate the increased 
stress of hypersecretion on the ǃ-cells (Liu et al., 2011). Similar to our findings, treatment of 
a high fat diet/STZ T2D mouse model with sitagliptin, a dipeptidyl peptidase-4 inhibitor 
and a new generation of antidiabetic drug, reversed the increased proportion and 
distribution of pancreatic ǂ-cells and thereby restored the ǂ- to ǃ-cell ratio following chronic 
11 week treatment. As with our study the reduction of the ǂ- to ǃ-cell ratio reflected the 
overall improvement of the glucose and lipid metabolism (Mu et al., 2006). The fact that 
metformin and rosiglitazone had a similar beneficial effect on the pancreatic ǂ- to ǃ-cell ratio 
as the honeybush extract is not surprising. Both metformin and rosiglitazone are established 
oral drugs for the treatment of T2D. Metformin, an activator of AMP-activated protein 
kinase (AMPK), not only ameliorates hyperglycaemia but has been shown to have 
additional beneficial effects on lipid metabolism. Activation of AMPK by metformin 
increases fatty acid oxidation by inactivation of acetyl-CoA carboxylase and suppression of 
lipogenesis by inhibiting SREBP-1 expression (Zhou et al., 2001). Rosiglitazone, a 
peroxisome proliferator activated receptors-Ǆ agonist, has been shown to improve insulin 
resistance and to have a positive effect on lipid metabolism in pre-diabetic animals by 
inhibiting malonyl-CoA and thereby increasing fatty acid oxidation in skeletal muscle and 
liver (Zhao et al., 2009). In addition, rosiglitazone has also been demonstrated to activate 
AMPK but via a different pathway from metformin (Fryer et al., 2002). Taken together, the 
positive morphological changes observed support the improved metabolic changes induced 
by chronic ingestion of aqueous honeybush extract. 
5. Conclusion 
The efficacy of an aqueous hot water honeybush extract in reducing hyperglycaemia was 
demonstrated in two different diabetic rodent models (STZ-induced T1D and diet-induced 
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T2D OBIR rat models). Furthermore, the extract promoted normoglycaemia in the diet-
induced T2D OBIR rat model and improved other metabolic aberrations associated with 
T2D. The high concentration of mangiferin and hesperidin in the extract could be partially 
responsible for the observed effects. 
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